Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. euroxpand

EuroXpand SIGNED

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroXpand project word cloud

Explore the words cloud of the EuroXpand project. It provides you a very rough idea of what is the project "EuroXpand" about.

profile    issue    excellent    millions    socio    hence    2022    position    post    cardiac    75    discoveries    safety    fail    clinical    invasive    industrialised    ami    demonstrated    affordable    possession    reinsertion    countries    efficacy    indicated    operative    outstanding    stempack    thanks    health    founder    myocardial    direct    centres    therapy    reference    global    euroxpand    demonstration    patented    35    hf    leader    surgical    prevention    stem    combined    model    cells    life    function    expansion    eacute    prevent    2021    pr    innovative    proof    83    context    billion    treatment    limiting    first    acute    cell    creation    cellprothera    pilot    heart    total    automate    successful    jobs    decreasing    death    nor    professional    least    characterised    thousands    2008    infarction    competitors    assets    business    cancer    recovery    burdensome    unlike    kit    worldwide    outcomes    euros    reg    indirect    treatments    founded    expectancy    patients    worked    public    stemxpand    turnover   

Project "EuroXpand" data sheet

The following table provides information about the project.

Coordinator		 CELLPROTHERA 

Organization address
address: 12 RUE DU PARC
city: MULHOUSE
postcode: 68100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 5˙000˙000 €
 EC max contribution 5˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLPROTHERA FR (MULHOUSE) coordinator 5˙000˙000.00

Map

 Project objective

Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 1,9 billion euros in 2021, associated to the creation of at least 40 direct jobs by 2022 and several thousands of indirect jobs, particularly in Cell Therapy Centres.

 Deliverables

List of deliverables.
Communication material (brochures, web…) Documents, reports 2020-02-12 17:33:26
Press Release - Project kick-off Documents, reports 2020-02-12 17:33:28

Take a look to the deliverables list in detail:  detailed list of EuroXpand deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EUROXPAND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EUROXPAND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More